Top 5 Life Science Angel Investors in Spain (May 2026)

Ritu Bansal-Mutalik is a Senior Director, Process Research and Development at ZymoChem.

Investment focus

Industry: Wellness, Life Science, Biotechnology
Stage:Seed
Geography: Spain

Investor stats

Total investments: 1
Lead/follow: 0% lead, 100% follow

Portfolio highlights

Libre Foods — Libre Foods is a biotech startup on a mission to liberate the food system and create a more free future for people, the planet, and animals. The company was founded in 2020 and is based in Barcelona, Catalonia, Spain.

Show all investments...

Arturo Elizondo is CEO of Clara Foods, a sustainable ingredients company making the world’s most comprehensive egg white substitute. Clara leverages advances in fermentation technology to bring an egg white to the table that is completely animal-free, far more sustainable, and free of salmonella without compromising the qualities we know and love.Prior to joining Clara Foods, Arturo worked at the investment bank Credit Suisse, U.S. Department of Agriculture, and under Supreme Court Justice Sonia Sotomayor.

Investment focus

Industry: Wellness, Life Science, Biotechnology
Stage:Seed, Pre-Seed
Geography: Spain, Switzerland

Investor stats

Total investments: 2
Lead/follow: no public data

Portfolio highlights

Libre Foods — Libre Foods is a biotech startup on a mission to liberate the food system and create a more free future for people, the planet, and animals. The company was founded in 2020 and is based in Barcelona, Catalonia, Spain.
Cultivated Biosciences — Cultivated - Creamy, dairy-free indulgence

Show all investments...

Arman Anatürk is Co-Founder @ FoodHack.

Investment focus

Industry: Biotechnology, Food and Beverage, Wellness
Stage:Seed, Pre-Seed
Geography: Spain, Israel, Germany

Investor stats

Total investments: 5
Round size: Seed $1.9M–$8.4M
Lead/follow: 20% lead, 80% follow

Portfolio highlights

Bosque Foods — Kinoko Labs develops the next generation of meat substitutes, starting with whole-cut meat items made from fungal mycelium produced organically. Headquartered in New York.
Libre Foods — Libre Foods is a biotech startup on a mission to liberate the food system and create a more free future for people, the planet, and animals. The company was founded in 2020 and is based in Barcelona, Catalonia, Spain.
Kynda — Keen 4 Greens offers a wide range of vegan products. Founded in 2019, Keen 4 Greens is based in Hamburg, Germany.

Show all investments...

Dr. Milad Alucozai is an Afghan-American neuroscientist, entrepreneur, biotech executive, and global investor with nearly two decades of experience in deep tech, primarily in life sciences. He pushes the boundaries of bioengineering and computational advancements, integrating machine learning and artificial intelligence into biology and medicine.With a strong commitment to commercializing transformative technologies and fostering startup ecosystems worldwide, he is a thought leader and formal mentor for entrepreneurs through organizations like Creative Destruction Lab and the Wyss Institute at Harvard Medical School.Currently, Milad is the head of Bio and Deep Tech at BoxOne Ventures, where he spearheads the firm’s investments in early-stage companies with breakthrough scientific ideas. With nearly 80 early-stage investments, they are recognized as one of North America’s most active venture firms. He is also a Venture Partner at Entrepreneur First, a global fund that has built over 500 companies from scratch with an enterprise value of $10bn. He supports founders with strategy, scaling, business development, securing growth capital, and leadership training, often being their first investor and guiding them from startup inception to IPOs or acquisitions.He started his career in translational neuroscience and multiphysics laboratories before transitioning into founding roles at biotech startups. He is part of the founding team at Mekonos, a San Francisco-based company creating a proprietary cell-engineering platform to support the future of cell and gene therapies. He was also part of the founding team at Corstem, which specialized in machine learning and artificial intelligence software and was later acquired by Circle Cardiovascular, a platform in over 1000 hospitals and more than 40 countries. At Accenture, Milad directed teams of data scientists, designers, and engineers in developing artificial intelligence platforms for global pharmaceutical companies and hospital networks.Milad serves as a Fellow in Healthcare Engineering at the Regenstrief Center. In 2020, he served as an External Advisor to AstraZeneca. He was recognized as a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program. As a George J. Mitchell Scholar, he completed his master’s in Immunology and earned his doctorate from the Richard M. Fairbanks School of Public Health.

Investment focus

Industry: Biotechnology, Health Care, Medical
Stage:Seed, Series A, Pre-Seed
Geography: United States, Canada, United Kingdom

Investor stats

Total investments: 47
Round size: Seed $91k–$4.5M; Pre-Seed $107k–$1.4M; Series A $25M–$60M
Lead/follow: 9% lead, 91% follow

Portfolio highlights

Arpeggio Bio — Arpeggio Biosciences leverages state of the art sequencing approaches coupled with powerful machine learning to uncover novel insights into a compound's biological mechanism of action.The company is diverse set of molecular biologists, computer scientists, and biotechnology enthusiasts passionate about understanding where, why, and howtherapeutics work.
Future Fields — Future Fields Cellular Agriculture: Serum-Free Growth Media Supplements and Recombinant Proteins - Optimized for the Future of Food.
Eigen Therapeutics — Eigen Therapeutics is a biotechnology company developing combination therapeutics for cancer. The company is in the research and development of synergistic therapies that improve efficacy while reducing the toxicity of small molecule therapies and immunotherapies, enabling physicians to get access to novel drugs in areas of unmet medical needs.

Show all investments...